ADE LLC’s Rigel Pharmaceuticals RIGL Stock Holding History

ADE LLC’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-230	Closed	-$8K	–	292
2020 Q4	$8K	Buy	+230	New	+$6.66K	0.01%	272

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ADE LLC's RIGL Position: Q1 2021 in Review

ADE LLC sold out of Rigel Pharmaceuticals (RIGL) in Q1 2021, closing a stake of 230 shares — an estimated $8K sold.

ADE LLC first reported a position in RIGL in Q4 2020 and held it in 1 quarter. The position peaked at $8K in Q4 2020. 152 funds tracked by Wall St. Rank hold RIGL as of Q1 2021.

ADE LLC reported no remaining Rigel Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
ADE LLC sold 230 Rigel Pharmaceuticals shares in Q1 2021, an estimated $8K.
ADE LLC first reported a position in Rigel Pharmaceuticals in Q4 2020 and held it in 1 quarter.
ADE LLC's Rigel Pharmaceuticals position peaked at $8K in Q4 2020.
152 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2021.

Based on ADE LLC's 13F filing for Q1 2021, filed 16 Apr 2021.